Akira Nishiyama Selected Research

olmesartan

1/2018	Chronic AT1 blockade improves glucose homeostasis in obese OLETF rats.
1/2018	Effects of Olmesartan and Azilsartan on Albuminuria and the Intrarenal Renin-Angiotensin System.
10/2016	Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients.
4/2015	Role of intrarenal (pro)renin receptor in ischemic acute kidney injury in rats.
8/2013	Angiotensin receptor-mediated oxidative stress is associated with impaired cardiac redox signaling and mitochondrial function in insulin-resistant rats.
5/2013	RAS inhibition attenuates cognitive impairment by reducing blood- brain barrier permeability in hypertensive subjects.
1/2013	Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats.
1/2013	Calcium channel blocker enhances beneficial effects of an angiotensin II AT1 receptor blocker against cerebrovascular-renal injury in type 2 diabetic mice.
5/2012	Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
3/2012	Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Akira Nishiyama Research Topics

Disease

83	Hypertension (High Blood Pressure) 11/2021 - 01/2001
27	Fibrosis (Cirrhosis) 02/2021 - 10/2005
25	Proteinuria 02/2022 - 01/2004
22	Albuminuria 01/2021 - 09/2008
19	Type 2 Diabetes Mellitus (MODY) 11/2021 - 09/2008
18	Insulin Resistance 01/2021 - 10/2007
18	Diabetic Nephropathies (Diabetic Nephropathy) 01/2019 - 10/2004
16	Neoplasms (Cancer) 09/2022 - 09/2014
16	Chronic Renal Insufficiency 11/2021 - 01/2009
15	Inflammation (Inflammations) 01/2022 - 01/2008
15	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 05/2010
12	Wounds and Injuries (Trauma) 01/2022 - 04/2005
12	Obesity 11/2021 - 02/2012
12	Ischemia 01/2021 - 11/2003
9	Body Weight (Weight, Body) 01/2022 - 01/2002
8	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 10/2005
8	Glucose Intolerance 01/2022 - 10/2007
8	Hypoxia (Hypoxemia) 06/2021 - 09/2009
8	Reperfusion Injury 01/2021 - 05/2005
8	Hypertrophy 01/2019 - 07/2007
7	IGA Glomerulonephritis (IGA Nephropathy) 01/2022 - 05/2006
7	Anemia 06/2021 - 09/2017
6	Hyperglycemia 11/2021 - 10/2004
6	Kidney Diseases (Kidney Disease) 12/2020 - 05/2006
6	Stroke (Strokes) 11/2018 - 05/2006
5	Colorectal Neoplasms (Colorectal Cancer) 11/2021 - 01/2019
5	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 11/2003
4	Hemorrhage 04/2022 - 01/2018
4	Dyslipidemias (Dyslipidemia) 01/2022 - 12/2012
4	Glycosuria 07/2020 - 12/2015
4	Necrosis 01/2019 - 11/2003
4	Heart Failure 01/2018 - 04/2007
4	Sclerosis 03/2010 - 07/2005
3	Fistula 04/2022 - 07/2015
3	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 01/2020
3	Polyps 11/2021 - 06/2021
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/2021 - 06/2021

Drug/Important Bio-Agent (IBA)

49	Angiotensin IIIBA 01/2021 - 02/2002
43	SaltsIBA 01/2022 - 01/2003
31	AldosteroneIBA 01/2022 - 01/2004
31	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2004
28	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 03/2005
23	AngiotensinogenIBA 01/2021 - 01/2003
21	ReninIBA 01/2020 - 02/2002
16	Prorenin ReceptorIBA 11/2020 - 05/2006
15	Antihypertensive Agents (Antihypertensives)IBA 09/2022 - 09/2007
15	SodiumIBA 01/2022 - 03/2003
15	Messenger RNA (mRNA)IBA 11/2021 - 05/2006
15	olmesartanIBA 01/2018 - 07/2004
13	Eplerenone (Inspra)FDA LinkGeneric 01/2021 - 04/2004
13	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2013 - 01/2001
12	Angiotensin Receptor AntagonistsIBA 01/2022 - 08/2008
12	Sodium-Glucose Transporter 2 InhibitorsIBA 11/2021 - 05/2016
11	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2022 - 04/2012
10	AngiotensinsIBA 01/2022 - 01/2003
10	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2021 - 04/2005
10	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2014 - 05/2005
9	CreatinineIBA 01/2021 - 08/2011
9	Insulin (Novolin)FDA Link 01/2020 - 10/2007
8	Peptides (Polypeptides)IBA 01/2020 - 10/2004
7	Erythropoietin FDA Link 01/2021 - 02/2016
7	Hydralazine (Apresoline)FDA LinkGeneric 03/2020 - 03/2004
7	CateninsIBA 01/2020 - 03/2015
6	AlbuminsIBA 01/2021 - 09/2008
6	Chymases (Chymase)IBA 11/2018 - 08/2008
6	candesartanIBA 01/2018 - 10/2003
6	Superoxides (Superoxide)IBA 01/2014 - 02/2003
6	tempolIBA 01/2012 - 03/2004
6	CollagenIBA 03/2011 - 01/2005
5	Retinaldehyde (Retinal)IBA 10/2022 - 03/2012
5	Pharmaceutical PreparationsIBA 02/2022 - 01/2009
5	Spironolactone (Aldactone)FDA LinkGeneric 01/2022 - 11/2013
5	Drinking WaterIBA 01/2022 - 07/2004
5	Immunoglobulin A (IgA)IBA 01/2022 - 05/2006
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2014
5	Sodium-Glucose Transport ProteinsIBA 01/2020 - 12/2015
5	aliskiren FDA Link 10/2018 - 05/2010
5	AntioxidantsIBA 01/2018 - 03/2006
4	Blood Glucose (Blood Sugar)IBA 11/2021 - 09/2008
4	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 06/2021 - 02/2016
4	esaxerenoneIBA 02/2021 - 01/2019
4	Transcription Factors (Transcription Factor)IBA 01/2021 - 11/2013
4	Adenine FDA LinkGeneric 12/2020 - 09/2017
4	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2020 - 06/2007
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 10/2020 - 06/2009
4	Valsartan (Vals)FDA Link 03/2020 - 08/2008
4	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2018 - 09/2011
4	Renin InhibitorsIBA 10/2018 - 05/2010
4	Type 1 Angiotensin ReceptorIBA 01/2017 - 10/2003
4	Epoxide HydrolasesIBA 07/2015 - 02/2013
4	FructoseIBA 11/2013 - 09/2009
4	Angiotensin II Type 1 Receptor BlockersIBA 01/2013 - 09/2008
3	Urea (Carbamide)FDA LinkGeneric 01/2022 - 07/2020
3	Mineralocorticoid Receptor AntagonistsIBA 01/2022 - 03/2010
3	Triglycerides (Triacylglycerol)IBA 01/2022 - 01/2018

Therapy/Procedure

18	Therapeutics 03/2021 - 07/2005
5	Surgical Instruments (Clip) 04/2022 - 03/2011
5	Nephrectomy 06/2021 - 11/2003
4	Denervation 01/2020 - 11/2003
4	Oral Administration 06/2018 - 12/2010